Ethyl Acetate

Ethyl Acetate

SCHEMBL7428573

CCOC(C)=O.CCOCC.CCOCC.CCOCC.CCOCC.CCOCC

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.82
LMNA P02545 1/20 0.82
HSD17B10 Q99714 1/20 0.82
TSHR P16473 1/20 0.64
GAA P10253 2/20 0.46
ALOX15 P16050 1/20 0.46
MGAM O43451 1/20 0.46
SI P14410 1/20 0.46
MGAM2 Q2M2H8 1/20 0.46
SOAT1 P35610 1/20 0.46
THRB P10828 1/20 0.43
TRPA1 O75762 1/20 0.42
GLO1 Q04760 1/20 0.41
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
CHRM5 P08912 2/20 0.39
CHRM1 P11229 2/20 0.39
CHRM3 P20309 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Acetate SCHEMBL18149 1.00 ALDH1A1 (0.82) ALDH1A1LMNAHSD17B10TSHRGAA
Ethyl Acetate SCHEMBL17007297 1.00 ALDH1A1 (0.82) ALDH1A1LMNAHSD17B10TSHRGAA
Ethyl Acetate SCHEMBL7232077 1.00 ALDH1A1 (0.82) ALDH1A1LMNAHSD17B10TSHRGAA
Ethyl Acetate SCHEMBL2122965 1.00 ALDH1A1 (0.82) ALDH1A1LMNAHSD17B10TSHRGAA
Ethyl Acetate SCHEMBL7465979 1.00 ALDH1A1 (0.82) ALDH1A1LMNAHSD17B10TSHRGAA
Ethyl Acetate SCHEMBL7341346 1.00 ALDH1A1 (0.82) ALDH1A1LMNAHSD17B10TSHRGAA
Ethyl Acetate SCHEMBL8008056 1.00 ALDH1A1 (0.82) ALDH1A1LMNAHSD17B10TSHRGAA
Ethyl Acetate SCHEMBL3113295 1.00 ALDH1A1 (0.82) ALDH1A1LMNAHSD17B10TSHRGAA
Ethyl Acetate SCHEMBL10004052 1.00 ALDH1A1 (0.82) ALDH1A1LMNAHSD17B10TSHRGAA
Ethyl Acetate SCHEMBL9675934 1.00 ALDH1A1 (0.82) ALDH1A1LMNAHSD17B10TSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024149261-A1 INHIBITOR OF COMPLEMENT FACTOR B 南京正大天晴制药有限公司 2024-07-18 WO disclosed
CN-113024490-B Preparation method of entecavir intermediate 南通诺泰生物医药技术有限公司 2024-05-14 CN disclosed
CN-111527099-B Selective inhibitors of protein arginine methyltransferase 5 (PRMT 5) 普莱鲁德疗法有限公司 2024-03-22 CN disclosed
CN-117736137-A Preparation method of pirenzenenaphthalene impurity 北京新康哌森医药科技有限公司 2024-03-22 CN disclosed
CN-117362343-A Compounds having selective TYK2/JAK1 inhibiting activity, pharmaceutical compositions containing the same and uses thereof 爱科诺生物医药(香港)有限公司 2024-01-09 CN disclosed
CN-116685576-A Cysteine protease inhibitors and methods of use thereof 美商帕迪斯生物科学公司 2023-09-01 CN disclosed
US-10266542-B2 EZH2 inhibitors Mirati Therapeutics, Inc. (US) 2019-04-23 US disclosed
CN-109053762-A PPAP hemiketal class compound, Its Preparation Method And Use 贵州省中国科学院天然产物化学重点实验室 2018-12-21 CN disclosed
US-20180265517-A1 EZH2 Inhibitors Mirati Therapeutics, Inc. 2018-09-20 US disclosed
EP-1117651-A1 NEW BIS-BENZIMIDAZOLES Bayer Aktiengesellschaft (DE) 2001-07-25 EP disclosed
WO-2000020401-A1 NEW BIS-BENZIMIDAZOLES BAYER AKTIENGESELLSCHAFT (DE) 2000-04-13 WO disclosed
EP-0613897-B1 Piperidine derivatives with antihistaminic and antileukotriene activity KOWA CO (JP) 1997-01-22 EP disclosed
US-5420143-A Antihistamines and antileukotrienes KOWA CO., LTD. (JP) 1995-05-30 US disclosed
EP-0613897-A1 Piperidine derivatives with antihistaminic and antileukotriene activity KOWA CO. LTD. (JP) 1994-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180265517-A1 EZH2 Inhibitors EZH2, BMI1, EED ALDH1A1 1969/4885LMNA 3377/4885HSD17B10 2012/4885
US-10266542-B2 EZH2 inhibitors EZH2, BMI1, EED ALDH1A1 1969/4885LMNA 3377/4885HSD17B10 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.